Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Trading Down 3.2 %

PULM stock opened at $2.09 on Tuesday. The business’s 50-day moving average price is $1.82 and its two-hundred day moving average price is $1.88. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $3.14. The firm has a market cap of $7.63 million, a PE ratio of -0.54 and a beta of 0.92.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter. Pulmatrix had a negative net margin of 193.49% and a negative return on equity of 63.94%. The firm had revenue of $2.20 million during the quarter.

Institutional Trading of Pulmatrix

Several hedge funds and other institutional investors have recently modified their holdings of PULM. Vanguard Group Inc. increased its position in Pulmatrix by 62.9% during the fourth quarter. Vanguard Group Inc. now owns 35,082 shares of the biotechnology company’s stock worth $65,000 after buying an additional 13,548 shares during the last quarter. Susquehanna International Group LLP acquired a new position in shares of Pulmatrix in the first quarter valued at approximately $73,000. Mariner LLC acquired a new stake in Pulmatrix during the fourth quarter worth approximately $97,000. Citadel Advisors LLC acquired a new stake in Pulmatrix during the second quarter worth approximately $141,000. Finally, Renaissance Technologies LLC grew its position in Pulmatrix by 7.3% during the second quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock worth $560,000 after buying an additional 8,300 shares in the last quarter. Institutional investors and hedge funds own 11.84% of the company’s stock.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.